Leuprolide Acetate - CAS 74381-53-6
Catalog number:
74381-53-6
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
COA:
Inquire
Targets:
GNRH Receptor
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
Leuprorelin; Leuprorelin Acetate; Lupron; Lupron Depot; Lupron Depot-3 Month; Lupron Depot-4 Month; Lupron Depot-Ped; Viadur; Carcinil; Enanton; Enantone; Enantone-Gyn; Ginecrin; Leuplin; Lucrin; Lucrin Depot; Procren; Procrin; Prostap; Trenantone; Uno-En
MSDS:
Inquire
1.Analysis of subsequent surgery rates among endometriosis patients who underwent surgery with and without concomitant leuprolide acetate therapy.
Soliman AM1, Bonafede M2, Farr AM2, Castelli-Haley J1, Winkel C3. Curr Med Res Opin. 2016 Mar 30:1-10. [Epub ahead of print]
Objective To compare subsequent endometriosis-related surgery following initial laparoscopy among women treated with leuprolide acetate (LA) or other endometriosis therapies versus women who received no pharmacotherapy. Research design and methods This retrospective cohort analysis utilized MarketScan Commercial claims data. Women with endometriosis aged 18-49 who underwent laparoscopy between 1 January 2005 and 31 December 2011 were identified using diagnosis and procedures codes and were categorized into four cohorts based on claims within 90 days of laparoscopy: surgery plus adherent LA, surgery plus non-adherent LA, surgery plus other therapy, and surgery alone. Patients with proportion of days covered ≥0.80 in the 6 months after laparoscopy were considered adherent to LA. Main outcome measures Subsequent endometriosis-related surgery (laparoscopy, laparotomy or other excision/ablation/fulguration of endometriosis lesions, oophorectomy, or hysterectomy) was measured in the 6 and 12 months following initial laparoscopy.
2.Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer.
Shore ND1, Chu F2, Moul J3, Saltzstein D4, Concepcion R5, McLane JA6, Atkinson S7, Yang A7, Crawford ED8. BJU Int. 2016 Mar 17. doi: 10.1111/bju.13482. [Epub ahead of print]
OBJECTIVE: To determine whether luteinising hormone-releasing hormone (LHRH) agonist, ATRIGEL® polymer-delivered, subcutaneous, leuprolide acetate (ADSC-LA), formulations suppressed serum testosterone to concentrations of ≤20 ng/dL.
3.A Fast and Sensitive Method for the Detection of Leuprolide Acetate: A High-Throughput Approach for the In Vitro Evaluation of Liquid Crystal Formulations.
Báez-Santos YM1, Otte A1, Park K1,2. Anal Chem. 2016 Apr 22. [Epub ahead of print]
The suitability of using fluorescence spectroscopy to rapidly assay drug release by quantifying the time-dependent increase in total intrinsic protein fluorescence was assessed. Leuprolide acetate, a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH or LHRH), is the active pharmaceutical ingredient used to treat a wide range of sex hormone-related disorders, including advanced prostatic cancer, endometriosis, and precocious puberty. During the in vitro evaluation of drug delivery technologies for leuprolide acetate, one of the most time-consuming steps is the detection and accurate quantification of leuprolide release from formulation candidates. Thus far, the dominant means for leuprolide detection involves conventional multistep high-performance liquid chromatography (HPLC) methods, requiring sampling, dilutions, sample filtration, and chromatography, which can take up to 40 min for each sample. With the increasing demand for assay adaptation to high-throughput format, here we sought to exploit fluorescence spectroscopy as a tool to develop a novel method to rapidly assay the in vitro release of leuprolide acetate.
4.Analysis of Adherence, Persistence, and Surgery Among Endometriosis Patients Treated with Leuprolide Acetate Plus Norethindrone Acetate Add-Back Therapy.
Soliman AM1, Bonafede M2, Farr AM2, Castelli-Haley J1, Winkel C3. J Manag Care Spec Pharm. 2016 May;22(5):573-87. doi: 10.18553/jmcp.2016.22.5.573.
BACKGROUND: Endometriosis affects over 10 million women in the United States. Depot leuprolide acetate (LA), a gonadotropin-releasing hormone agonist, has been used extensively for the treatment of women with endometriosis but is associated with hypoestrogenic symptoms and bone mineral density loss. The concomitant use of add-back therapies, specifically norethindrone acetate (NETA), can alleviate these adverse effects.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related GNRH Receptor Products


CAS 33515-09-2 Gonadorelin

Gonadorelin
(CAS: 33515-09-2)

Gonadorelin, a synthetic decapeptide prepared using solid phase peptide synthesis, is another name for gonadotropin-releasing hormone (GnRH) for evaluating th...

CAS 65807-02-5 Goserelin Acetate

Goserelin Acetate
(CAS: 65807-02-5)

CAS 148029-26-9 Alarelin

Alarelin
(CAS: 148029-26-9)

Alarelin, more commonly existed as Alarelin acetate, has been found to be a GnRH agonist that could delay the sexual maturation in rats.

CAS 53714-56-0 Leuprorelin

Leuprorelin
(CAS: 53714-56-0)

Leuprorelin is a gonadotropin-releasing hormone (GnRH) analogue used to treat prostate cancer and breast cancer.

Triptorelin pamoate
(CAS: 124508-66-3)

Triptorelin is a decapeptide as a GnRH (gonadotropin-releasing hormone) agonist under the development of Pfizer. It decreases pituitary secretion of gonadotropi...

CAS 214766-78-6 Degarelix acetate

Degarelix acetate
(CAS: 214766-78-6)

CAS 145781-92-6 Goserelin Acetate

Goserelin Acetate
(CAS: 145781-92-6)

Goserelin is a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. Goserelin binds to and activates pitui...

CAS 79561-22-1 Alarelin Acetate

Alarelin Acetate
(CAS: 79561-22-1)

Alarelin acetate is a synthetic Gonadotrophin-releasing hormone agonist. It is the acetate form of a hypothalamic peptide. It is a potent LH-RH agonist in rats ...

CAS 74381-53-6 Leuprolide Acetate

Leuprolide Acetate
(CAS: 74381-53-6)

CAS 57773-65-6 Deslorelin

Deslorelin
(CAS: 57773-65-6)

Deslorelin is a synthetic nonapeptide analogue of the natural gonadotrophin releasing hormone super-agonist (GnRH agonist) with potential antineoplastic activit...

CAS 86220-42-0 Nafarelin Acetate

Nafarelin Acetate
(CAS: 86220-42-0)

Nafarelin is a GnRH (gonadotropin-releasing hormone) agonist . Its proposed mechanism of action is the desensitization of pituitary gonadotropin-releasing hormo...

CAS 76712-82-8 Histrelin

Histrelin
(CAS: 76712-82-8)

Histrelin is a nonapeptide analog of GnRH (gonadotropin-releasing hormone) with added potency. When present in the bloodstream, it can act on gonadotropes. Hist...

CAS 34973-08-5 Gonadorelin acetate

Gonadorelin acetate
(CAS: 34973-08-5)

Gonadorelin a synthetic decapeptide prepared for gonadotropin-releasing hormone (GnRH), affects follicle stimulating hormones.

CAS 834153-87-6 Elagolix

Elagolix
(CAS: 834153-87-6)

Elagolix is a Gonadotropin-Releasing Hormone (GnRH) Antagonist. Elagolix inhibits gonadatropin releasing hormone (GnRH) receptors in the pituitary gland and ult...

CAS 832720-36-2 Elagolix sodium

Elagolix sodium
(CAS: 832720-36-2)

Elagolix is a selective gonadotropin-releasing hormone receptor (GnRHR) antagonist with KD of 54 pM. It is in phase III clinical trials for the treatment of end...

Chemical Structure

CAS 74381-53-6 Leuprolide Acetate

Quick Inquiry

Verification code

Featured Items